Skip to main content
. 2017 Nov 24;15(2):1580–1590. doi: 10.3892/ol.2017.7484

Table II.

Percentage of iNKT cells with expression of IL-4 or IFN-γ divided according to adverse prognostic factors.

Variable ZAP-70-positive patients ZAP-70-negative patients P-value
iNKT+IL-4+ (%) 37.86 (8.00–92.86) 30.19 (2.36–89.47) 0.049a
iNKT+IFN-γ+ (%) 22.23 (2.00–68.97) 25.00 (0.60–83.33) 0.495
iNKT+IFN-γ+/iNKT+IL-4+ ratio 0.60 (0.04–2.28) 0.89 (0.16–3.73) 0.046a

CD38-positive patients CD38-negative patients

iNKT+IL-4+ (%) 36.71 (8.00–92.86) 33.85 (2.36–89.47) 0.462
iNKT+IFN-γ+ (%) 21.43 (5.81–68.97) 25.55 (0.60–83.33) 0.382
iNKT+IFN-γ+/iNKT+IL-4+ ratio 0.57 (0.16–2.68) 0.77 (0.04–3.73) 0.176

del(17p13.1) and/or del(11q22.3) Without del(17p13.1), del(11q22.3)

iNKT+IL-4+ (%) 32.13 (12.07–55.56) 37.71 (2.36–92.86) 0.548
iNKT+IFN-γ+ (%) 16.08 (10.53–60.62) 24.00 (0.60–83.33) 0.064
iNKT+IFN-γ+/iNKT+IL-4+ ratio 0.53 (0.32–2.29) 0.71 (0.04–3.73) 0.365

The P-value was calculated using the Mann-Whitney U test.

a

P<0.05 was considered to indicate a statistically significant difference.